BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does BRIM Biotechnology, Inc. (6885) operate in?
BRIM Biotechnology, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is BRIM Biotechnology, Inc. (6885) current stock price?
As of the latest data, BRIM Biotechnology, Inc. stock price is NT$21.00, with a previous close of NT$21.00.
What is BRIM Biotechnology, Inc. (6885) current market capitalization?
BRIM Biotechnology, Inc. market cap is approximately 2.79 billion.
What is BRIM Biotechnology, Inc. (6885) Earnings Per Share (EPS)?
The trailing EPS is -NT$3.32.
Does BRIM Biotechnology, Inc. (6885) pay dividends?
No. BRIM Biotechnology, Inc. does not pay a dividend.
What is BRIM Biotechnology, Inc. (6885) beta (volatility) score?
BRIM Biotechnology, Inc. has a beta of 0.731, indicating lower volatility than the overall market.
